O6-Methylguanine DNA Methyltransferase (MGMT) Deficiency and Response to Aranoza-Based Therapy in Patients with Neuroendocrine Tumors


Introduction: Aranoza (3-α-L-arabinopyranosyl-1-methyl-nitrosourea) – nitrosourea derivative, as STZ. O6-methylguanine DNA methyltransferase (MGMT) is an enzyme implicated in chemotherapy resistance to alkylating agents and its low levels are associated with sensitivity to them.

Aim(s): To investigate the relationship between response to Aranoza-based therapy and MGMT expression.

Materials and methods: The MGMT expression was measured in 37 pts by immunohistochemistry using paraffin-embedded tissues. Tumors were scored as ‘‘intact’’ when the rate of positive cells was more than 10% with the intensity of staining 1+ and more. All consecutive pts with WD NETs treated with Аranoza alone or in combination with capecitabine, doxorubicin or temozolomide. Treatment efficacy was evaluated according to RECIST criteria v.1.0. The median PFS was calculated using Kaplan-Meier method.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Polozkova S, Stepanova E, Delektorskaya V, Kozlov N, Gorbunova V,

Keywords: aranoza, MGMT, chemotherapy, NETs,

To read the full abstract, please log into your ENETS Member account.